FDA approves intranasal esketamine formulation

In each trial submitted, all patients were started on a new antidepressant drug, and given a course of esketamine treatment or a placebo. But in two others trials, the drug did not statistically outperform placebo treatment. All the subjects had been given a diagnosis of treatment-resistant depression, or T.R.D., having previously failed multiple courses of drug treatment.

Source: www.nytimes.com